Background: Cefotaxime is commonly used empirically in bacterial meningitis, sepsis and methicillin-sensitive Staphylococcus aureus (MSSA) bacteraemia, but optimal paediatric dosing is unclear, particularly with respect to achieving adequate cerebrospinal fluid (CSF) exposure. The population pharmacokinetics (popPK) of unbound cefotaxime in serum and CSF have not been previously reported. This study aimed to (i) develop a […]
